Navigation Links
Innovative solution to help reduce the waiting times for kidney transplants

e waiting list is long and about 2 % of them die each year waiting. The longer they wait for a transplant, the worse their outcomes. Research shows that receiving a kidney from a living donor gives the recipient the best survival rates of at least 15 to 20 years. On the other hand a transplant from a deceased donor lasts from 10 to 15 years. But the incompatibility factor again plays an important role which reduces the chance of transplantation. Cole said that paired kidney exchange is now used in the United States, Europe and Asia. This is an important initiative, an opportunity to save many lives. Hence in conclusion he said that they are putting in their best effort to set up a computerized pair registry for the benefit of the patients who are waiting for a kidney transplant.


'"/>




Page: 1 2

Related medicine news :

1. Innovative device aids in advanced heart failure
2. Innovative footwear may prevent fall in elderly
3. Innovative yeast genome may handle Cancer Clues
4. Personalized Medicine and Innovative Pharmaceuticals
5. Creation of Cytomegalovirus Vaccine by an Innovative Method
6. Innovative Method for Creating a Human Cytomegalovirus Vaccine Outlined
7. Innovative treatment for Dementia
8. Innovative treatment for Skin Cancer
9. Innovative Movies Show Real-Time Immune-Cell Activity within Tumors
10. Research In A New Direction To Develop Innovative Psychotropic Drugs
11. Autism Expert Creates Innovative Intervention Program
Post Your Comments:
Breaking Medicine Technology:Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 1The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 2The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 3The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 4Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 1Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 2Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 3Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 4Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 1Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 2Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 3Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 4
Other Medicine Technology:Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12